|
Originally published In Press as doi:10.1074/jbc.M011761200 on February 7, 2001
J. Biol. Chem., Vol. 276, Issue 18, 14867-14874, May 4, 2001
Pathways of Epoxyeicosatrienoic Acid Metabolism in
Endothelial Cells
IMPLICATIONS FOR THE VASCULAR EFFECTS OF SOLUBLE EPOXIDE
HYDROLASE INHIBITION*
Xiang
Fang ,
Terry L.
Kaduce ,
Neal L.
Weintraub§,
Shawn
Harmon ,
Lynn M.
Teesch¶,
Christophe
Morisseau ,
David A.
Thompson ,
Bruce D.
Hammock , and
Arthur A.
Spector §
From the Departments of Biochemistry,
§ Internal Medicine, and ¶ Molecular Analysis Facility,
College of Medicine, University of Iowa, Iowa City, Iowa 52242 and
the Department of Entomology and Cancer Research Center,
University of California, Davis, California 95616
Epoxyeicosatrienoic acids (EETs) are
products of cytochrome P-450 epoxygenase that possess important
vasodilating and anti-inflammatory properties. EETs are converted to
the corresponding dihydroxyeicosatrienoic acid (DHET) by soluble
epoxide hydrolase (sEH) in mammalian tissues, and inhibition of sEH has
been proposed as a novel approach for the treatment of hypertension. We
observed that sEH is present in porcine coronary endothelial cells
(PCEC), and we found that low concentrations of
N,N'-dicyclohexylurea (DCU), a selective sEH inhibitor,
have profound effects on EET metabolism in PCEC cultures. Treatment
with 3 µM DCU reduced cellular conversion of 14,15-EET to
14,15-DHET by 3-fold after 4 h of incubation, with a concomitant
increase in the formation of the novel -oxidation products
10,11-epoxy-16:2 and 8,9-epoxy-14:1. DCU also markedly enhanced the
incorporation of 14,15-EET and its metabolites into PCEC lipids. The
most abundant product in DCU-treated cells was 16,17-epoxy-22:3, the
elongation product of 14,15-EET. Another novel metabolite,
14,15-epoxy-20:2, was present in DCU-treated cells. DCU also caused a
4-fold increase in release of 14,15-EET when the cells were stimulated
with a calcium ionophore. Furthermore, DCU decreased the conversion of
[3H]11,12-EET to 11,12-DHET, increased 11,12-EET
retention in PCEC lipids, and produced an accumulation of the partial
-oxidation product 7,8-epoxy-16:2 in the medium. These findings
suggest that in addition to being metabolized by sEH, EETs are
substrates for -oxidation and chain elongation in endothelial cells
and that there is considerable interaction among the three pathways.
The modulation of EET metabolism by DCU provides novel insight into the
mechanisms by which pharmacological or molecular inhibition of sEH
effectively treats hypertension.
*
This study was supported by National Institutes of Health
Program Project Grants HL49264 and HL62984 (to A. A. S. and
N. L. W.), by an American Heart Association Heartland Affiliate
Beginning Grant-in-aid 0060413Z (to X. F.), by an American Heart
Association Clinician-Scientist Award 96004540 (to N. L. W.), by
NIEHS Grant R01 ES02710, the NIEHS Superfund Basic Research Program P42
ES04699, and NIEHS Center P30 ES05707 (to B. D. H.) from the National
Institutes of Health, and by National Institutes of Health Training
Grant HL07013 (to D. A. T.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

To whom correspondence should be addressed: Dept. of
Biochemistry, 4-403 BSB, University of Iowa, Iowa City, IA 52242. Tel.: 319-335-7913; Fax: 319-335-9570; E-mail:
arthur-spector@uiowa.edu.
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. J. Iliff, R. Wang, D. C. Zeldin, and N. J. Alkayed
Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels
Am J Physiol Heart Circ Physiol,
May 1, 2009;
296(5):
H1352 - H1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Spector
Arachidonic acid cytochrome P450 epoxygenase pathway
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S52 - S56.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Morin, M. Sirois, V. Echave, M. M. Gomes, and E. Rousseau
EET Displays Anti-Inflammatory Effects in TNF-{alpha} Stimulated Human Bronchi: Putative Role of CPI-17
Am. J. Respir. Cell Mol. Biol.,
February 1, 2008;
38(2):
192 - 201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Corenblum, V. E. Wise, K. Georgi, B. D. Hammock, P. A. Doris, and M. Fornage
Altered Soluble Epoxide Hydrolase Gene Expression and Function and Vascular Disease Risk in the Stroke-Prone Spontaneously Hypertensive Rat
Hypertension,
February 1, 2008;
51(2):
567 - 573.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Hamanaka, M.-Y. Jian, D. S. Weber, D. F. Alvarez, M. I. Townsley, A. B. Al-Mehdi, J. A. King, W. Liedtke, and J. C. Parker
TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs
Am J Physiol Lung Cell Mol Physiol,
October 1, 2007;
293(4):
L923 - L932.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Y. Ng, Y. Huang, L. M. Reddy, J. R. Falck, E. T. Lin, and D. L. Kroetz
Cytochrome P450 Eicosanoids are Activators of Peroxisome Proliferator-Activated Receptor {alpha}
Drug Metab. Dispos.,
July 1, 2007;
35(7):
1126 - 1134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Spector and A. W. Norris
Action of epoxyeicosatrienoic acids on cellular function
Am J Physiol Cell Physiol,
March 1, 2007;
292(3):
C996 - C1012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Campbell and J. R. Falck
Arachidonic Acid Metabolites as Endothelium-Derived Hyperpolarizing Factors
Hypertension,
March 1, 2007;
49(3):
590 - 596.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Fang, F. M. Faraci, T. L. Kaduce, S. Harmon, M. L. Modrick, S. Hu, S. A. Moore, J. R. Falck, N. L. Weintraub, and A. A. Spector
20-Hydroxyeicosatetraenoic acid is a potent dilator of mouse basilar artery: role of cyclooxygenase
Am J Physiol Heart Circ Physiol,
November 1, 2006;
291(5):
H2301 - H2307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Seubert, C. J. Sinal, J. Graves, L. M. DeGraff, J. A. Bradbury, C. R. Lee, K. Goralski, M. A. Carey, A. Luria, J. W. Newman, et al.
Role of Soluble Epoxide Hydrolase in Postischemic Recovery of Heart Contractile Function
Circ. Res.,
August 18, 2006;
99(4):
442 - 450.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Davis, C. Morisseau, J. W. Newman, T. L. Pedersen, B. D. Hammock, and R. H. Weiss
Attenuation of Vascular Smooth Muscle Cell Proliferation by 1-Cyclohexyl-3-dodecyl Urea Is Independent of Soluble Epoxide Hydrolase Inhibition
J. Pharmacol. Exp. Ther.,
February 1, 2006;
316(2):
815 - 821.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Fang, S. Hu, B. Xu, G. D. Snyder, S. Harmon, J. Yao, Y. Liu, B. Sangras, J. R. Falck, N. L. Weintraub, et al.
14,15-Dihydroxyeicosatrienoic acid activates peroxisome proliferator-activated receptor-{alpha}
Am J Physiol Heart Circ Physiol,
January 1, 2006;
290(1):
H55 - H63.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Liu, Y. Zhang, K. Schmelzer, T.-S. Lee, X. Fang, Y. Zhu, A. A. Spector, S. Gill, C. Morisseau, B. D. Hammock, et al.
The antiinflammatory effect of laminar flow: The role of PPAR{gamma}, epoxyeicosatrienoic acids, and soluble epoxide hydrolase
PNAS,
November 15, 2005;
102(46):
16747 - 16752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Fang, S. Hu, T. Watanabe, N. L. Weintraub, G. D. Snyder, J. Yao, Y. Liu, J. Y.-J. Shyy, B. D. Hammock, and A. A. Spector
Activation of Peroxisome Proliferator-Activated Receptor {alpha} by Substituted Urea-Derived Soluble Epoxide Hydrolase Inhibitors
J. Pharmacol. Exp. Ther.,
July 1, 2005;
314(1):
260 - 270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Jung, R. P. Brandes, I.-H. Kim, F. Schweda, R. Schmidt, B. D. Hammock, R. Busse, and I. Fleming
Soluble Epoxide Hydrolase Is a Main Effector of Angiotensin II-Induced Hypertension
Hypertension,
April 1, 2005;
45(4):
759 - 765.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. R. Smith, K. E. Pinkerton, T. Watanabe, T. L. Pedersen, S. J. Ma, and B. D. Hammock
Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor
PNAS,
February 8, 2005;
102(6):
2186 - 2191.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Fang, N. L. Weintraub, R. B. McCaw, S. Hu, S. D. Harmon, J. B. Rice, B. D. Hammock, and A. A. Spector
Effect of soluble epoxide hydrolase inhibition on epoxyeicosatrienoic acid metabolism in human blood vessels
Am J Physiol Heart Circ Physiol,
December 1, 2004;
287(6):
H2412 - H2420.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Le Quere, E. Plee-Gautier, P. Potin, S. Madec, and J.-P. Salaun
Human CYP4F3s are the main catalysts in the oxidation of fatty acid epoxides
J. Lipid Res.,
August 1, 2004;
45(8):
1446 - 1458.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Yu, B. B. Davis, C. Morisseau, B. D. Hammock, J. L. Olson, D. L. Kroetz, and R. H. Weiss
Vascular localization of soluble epoxide hydrolase in the human kidney
Am J Physiol Renal Physiol,
April 1, 2004;
286(4):
F720 - F726.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Chuang, C. Helvig, M. Taimi, H. A. Ramshaw, A. H. Collop, M.'a. Amad, J. A. White, M. Petkovich, G. Jones, and B. Korczak
CYP2U1, a Novel Human Thymus- and Brain-specific Cytochrome P450, Catalyzes {omega}- and ({omega}-1)-Hydroxylation of Fatty Acids
J. Biol. Chem.,
February 20, 2004;
279(8):
6305 - 6314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. F. Alvarez, E.-A. B. Gjerde, and M. I. Townsley
Role of EETs in regulation of endothelial permeability in rat lung
Am J Physiol Lung Cell Mol Physiol,
February 1, 2004;
286(2):
L445 - L451.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Fornage, E. Boerwinkle, P. A. Doris, D. Jacobs, K. Liu, and N. D. Wong
Polymorphism of the Soluble Epoxide Hydrolase Is Associated With Coronary Artery Calcification in African-American Subjects: The Coronary Artery Risk Development In Young Adults (CARDIA) Study
Circulation,
January 27, 2004;
109(3):
335 - 339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Kaduce, X. Fang, S. D. Harmon, C. L. Oltman, K. C. Dellsperger, L. M. Teesch, V. R. Gopal, J. R. Falck, W. B. Campbell, N. L. Weintraub, et al.
20-Hydroxyeicosatetraenoic Acid (20-HETE) Metabolism in Coronary Endothelial Cells
J. Biol. Chem.,
January 23, 2004;
279(4):
2648 - 2656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, L. Lin, J. Jiang, Y. Wang, Z. Y. Lu, J. A. Bradbury, F. B. Lih, D. W. Wang, and D. C. Zeldin
Up-Regulation of Endothelial Nitric-Oxide Synthase by Endothelium-Derived Hyperpolarizing Factor Involves Mitogen-Activated Protein Kinase and Protein Kinase C Signaling Pathways
J. Pharmacol. Exp. Ther.,
November 1, 2003;
307(2):
753 - 764.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Watanabe, C. Morisseau, J. W. Newman, and B. D. Hammock
IN VITRO METABOLISM OF THE MAMMALIAN SOLUBLE EPOXIDE HYDROLASE INHIBITOR, 1-CYCLOHEXYL-3-DODECYL-UREA
Drug Metab. Dispos.,
July 1, 2003;
31(7):
846 - 853.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cronin, S. Mowbray, H. Durk, S. Homburg, I. Fleming, B. Fisslthaler, F. Oesch, and M. Arand
The N-terminal domain of mammalian soluble epoxide hydrolase is a phosphatase
PNAS,
February 18, 2003;
100(4):
1552 - 1557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Fang, N. L. Weintraub, C. L. Oltman, L. L. Stoll, T. L. Kaduce, S. Harmon, K. C. Dellsperger, C. Morisseau, B. D. Hammock, and A. A. Spector
Human coronary endothelial cells convert 14,15-EET to a biologically active chain-shortened epoxide
Am J Physiol Heart Circ Physiol,
December 1, 2002;
283(6):
H2306 - H2314.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Lu, M. VanRollins, and H.-C. Lee
Stereospecific Activation of Cardiac ATP-Sensitive K+ Channels by Epoxyeicosatrienoic Acids: A Structural Determinant Study
Mol. Pharmacol.,
November 1, 2002;
62(5):
1076 - 1083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. A. Cowart, S. Wei, M.-H. Hsu, E. F. Johnson, M. U. Krishna, J. R. Falck, and J. H. Capdevila
The CYP4A Isoforms Hydroxylate Epoxyeicosatrienoic Acids to Form High Affinity Peroxisome Proliferator-activated Receptor Ligands
J. Biol. Chem.,
September 13, 2002;
277(38):
35105 - 35112.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Davis, D. A. Thompson, L. L. Howard, C. Morisseau, B. D. Hammock, and R. H. Weiss
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation
PNAS,
February 6, 2002;
(2002)
261710799.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Imig, X. Zhao, J. H. Capdevila, C. Morisseau, and B. D. Hammock
Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension
Hypertension,
February 1, 2002;
39(2):
690 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. J. Roman
P-450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function
Physiol Rev,
January 1, 2002;
82(1):
131 - 185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Yang, L. Graham, S. Dikalov, R. P. Mason, J. R. Falck, J. K. Liao, and D. C. Zeldin
Overexpression of Cytochrome P450 CYP2J2 Protects against Hypoxia-Reoxygenation Injury in Cultured Bovine Aortic Endothelial Cells
Mol. Pharmacol.,
August 1, 2001;
60(2):
310 - 320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. C. Zeldin
Epoxygenase Pathways of Arachidonic Acid Metabolism
J. Biol. Chem.,
September 21, 2001;
276(39):
36059 - 36062.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. B. Davis, D. A. Thompson, L. L. Howard, C. Morisseau, B. D. Hammock, and R. H. Weiss
Inhibitors of soluble epoxide hydrolase attenuate vascular smooth muscle cell proliferation
PNAS,
February 19, 2002;
99(4):
2222 - 2227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. B. Campbell, C. Deeter, K. M. Gauthier, R. H. Ingraham, J. R. Falck, and P.-L. Li
14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of KCa channels
Am J Physiol Heart Circ Physiol,
May 1, 2002;
282(5):
H1656 - H1664.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|